- Home
- BBTX vs STTK Comparison
BBTX vs STTK Comparison
Compare BBTX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBTX | STTK |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 631.2M | 652.4M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBTX | STTK |
|---|---|---|
| Price | $16.95 | $5.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $15.40 |
| AVG Volume (30 Days) | N/A | ★ 945.0K |
| Earning Date | 12-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.72 |
| 52 Week High | N/A | $8.33 |
Technical Indicators
Market Signals| Indicator | BBTX | STTK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.99 |
| Support Level | N/A | $3.55 |
| Resistance Level | N/A | $5.98 |
| Average True Range (ATR) | 0.00 | 0.40 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 32.72 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.